M&T Bank Corp Exact Sciences Corp Transaction History

M&T Bank Corp

  • $27 Billion
  • Q1 2025

A detailed history of M&T Bank Corp transactions in Exact Sciences Corp stock. As of the latest transaction made, M&T Bank Corp holds 6,995 shares of EXAS stock, worth $392,979. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,995
Previous 7,963 12.16%
Holding current value
$392,979
Previous $447,000 32.44%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 30, 2025
SELL
$43.04 - $58.51 $41,662 - $56,637
-968 Reduced 12.16%
6,995 $302,000
Q4 2024

Feb 06, 2025
SELL
$49.33 - $71.97 $63,783 - $93,057
-1,293 Reduced 13.97%
7,963 $447,000
Q3 2024

Nov 15, 2024
BUY
$42.43 - $70.83 $119,058 - $198,748
2,806 Added 43.5%
9,256 $630,000
Q2 2024

Jul 31, 2024
SELL
$41.33 - $74.26 $661 - $1,188
-16 Reduced 0.25%
6,450 $272,000
Q1 2024

May 07, 2024
SELL
$56.27 - $73.77 $17,837 - $23,385
-317 Reduced 4.67%
6,466 $446,000
Q4 2023

Feb 06, 2024
SELL
$59.06 - $75.72 $145,760 - $186,876
-2,468 Reduced 26.68%
6,783 $501,000
Q3 2023

Nov 02, 2023
BUY
$65.94 - $99.04 $71,610 - $107,557
1,086 Added 13.3%
9,251 $631,000
Q2 2023

Aug 09, 2023
BUY
$62.68 - $95.05 $138,460 - $209,965
2,209 Added 37.09%
8,165 $766,000
Q1 2023

May 11, 2023
BUY
$47.19 - $70.77 $1,038 - $1,556
22 Added 0.37%
5,956 $403,000
Q4 2022

Feb 13, 2023
SELL
$30.35 - $53.15 $97,180 - $170,186
-3,202 Reduced 35.05%
5,934 $293,000
Q4 2022

Feb 13, 2023
BUY
$30.35 - $53.15 $277,277 - $485,578
9,136 New
9,136 $452,000
Q2 2022

Aug 05, 2022
SELL
$35.61 - $76.23 $1,175 - $2,515
-33 Reduced 0.52%
6,294 $244,000
Q1 2022

May 09, 2022
BUY
$57.56 - $82.54 $74,770 - $107,219
1,299 Added 25.84%
6,327 $442,000
Q4 2021

Feb 07, 2022
BUY
$72.5 - $100.68 $23,417 - $32,519
323 Added 6.87%
5,028 $391,000
Q3 2021

Oct 28, 2021
SELL
$90.24 - $124.05 $57,663 - $79,267
-639 Reduced 11.96%
4,705 $449,000
Q2 2021

Aug 13, 2021
BUY
$93.66 - $139.27 $72,492 - $107,794
774 Added 16.94%
5,344 $665,000
Q1 2021

May 06, 2021
SELL
$116.57 - $155.01 $456,371 - $606,864
-3,915 Reduced 46.14%
4,570 $602,000
Q4 2020

Feb 12, 2021
BUY
$99.61 - $142.12 $357,201 - $509,642
3,586 Added 73.2%
8,485 $1.13 Million
Q3 2020

Nov 06, 2020
BUY
$72.92 - $102.01 $52,502 - $73,447
720 Added 17.23%
4,899 $501,000
Q2 2020

Jul 29, 2020
SELL
$55.75 - $92.75 $656,344 - $1.09 Million
-11,773 Reduced 73.8%
4,179 $363,000
Q1 2020

May 14, 2020
SELL
$37.9 - $104.44 $28,387 - $78,225
-749 Reduced 4.48%
15,952 $926,000
Q4 2019

Feb 07, 2020
SELL
$77.66 - $99.74 $146,156 - $187,710
-1,882 Reduced 10.13%
16,701 $1.55 Million
Q3 2019

Nov 12, 2019
SELL
$90.37 - $122.49 $104,648 - $141,843
-1,158 Reduced 5.87%
18,583 $1.68 Million
Q2 2019

Aug 12, 2019
BUY
$89.51 - $118.04 $34,192 - $45,091
382 Added 1.97%
19,741 $2.33 Million
Q1 2019

May 15, 2019
SELL
$61.98 - $96.5 $2,851 - $4,439
-46 Reduced 0.24%
19,359 $1.68 Million
Q4 2018

Feb 01, 2019
BUY
$56.04 - $82.66 $1,457 - $2,149
26 Added 0.13%
19,405 $1.23 Million
Q3 2018

Nov 09, 2018
BUY
$48.29 - $80.6 $182,343 - $304,345
3,776 Added 24.2%
19,379 $1.53 Million
Q2 2018

Aug 10, 2018
SELL
$37.84 - $69.96 $26,715 - $49,391
-706 Reduced 4.33%
15,603 $933,000
Q1 2018

May 04, 2018
BUY
$39.82 - $57.53 $73,228 - $105,797
1,839 Added 12.71%
16,309 $658,000
Q4 2017

Feb 06, 2018
BUY
$46.49 - $60.51 $36,587 - $47,621
787 Added 5.75%
14,470 $760,000
Q3 2017

Nov 13, 2017
SELL
$37.05 - $47.12 $53,759 - $68,371
-1,451 Reduced 9.59%
13,683 $644,000
Q2 2017

Aug 11, 2017
BUY
N/A
15,134
15,134 $536,000

Others Institutions Holding EXAS

# of Institutions
645
Shares Held
157M
Call Options Held
1.74M
Put Options Held
1.56M
View Full List

About EXACT SCIENCES CORP

EXAS Quotes by TradingView
  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.94B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email